Beyond Air, Inc.XAIR
Price (close)
$3.17
Market cap
$3.0M
P/E
—
Revenue (TTM)
$7.7M
Net income
-$33.5M
Dividend yield
—
1-year total return
-93.2%
Net margin
-435.7%
Revenue growth
60.7%
Debt / equity
—
What Beyond Air, Inc. does.
are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators
by the LungFit ® PH system is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation
in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $873,000 | — | — | $1.2M | $3.7M | $7.7M |
| Net income | -$22.9M | -$43.2M | -$55.8M | -$60.2M | -$46.6M | -$33.2M |
| Free cash flow | -$20.5M | -$24.5M | -$36.9M | -$61.8M | -$44.1M | -$19.2M |
More on XAIR.
- Beyond Air, Inc. summary
- Beyond Air, Inc. financial statements
- Beyond Air, Inc. key metrics
- Beyond Air, Inc. health scores and style box
- Beyond Air, Inc. earnings
- Beyond Air, Inc. dividends
- Beyond Air, Inc. valuation
- Beyond Air, Inc. ownership and insiders
- Beyond Air, Inc. peers
Figures from Beyond Air, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.